Takeda’s Adcetris could soon be on the market in Europe as a second-line treatment for adults with CD30-positive cutaneous T-cell lymphoma (CTCL) after regulatory advisors backed expanding the drug’s scope.
GlaxoSmithKline and Innoviva have won European approval for the novel triple therapy inhaler Trelegy Ellipta, offering a new treatment option for patients with Chronic Obstructive Pulmonary Disorder (COPD).
The National Institute for Health and Care Excellence is backing routine NHS funding for Pfizer's Ibrance and Novartis' Kisqali to treat certain forms of breast cancer, after the firms agreed to provide them at a reduced price under the new process for appraising medicines.
Boehringer Ingelheim has won its first biosimilar approval in Europe with authorisation of Cyltezo for a range of chronic inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease and ulcerative colitis.
The Scottish Medicines Consortium (SMC) has published new advice accepting three new medicines for use by NHS Scotland, offering patients new treatment options for soft tissue sarcoma, acromegaly and hepatitis C